Low Molecular Weight Heparin (dalteparin)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Deep Vein Thrombosis
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Trial Timeline
Aug 1, 2002 → Jan 1, 2007
NCT ID
NCT00187408About Low Molecular Weight Heparin (dalteparin)
Low Molecular Weight Heparin (dalteparin) is a approved stage product being developed by Pfizer for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00187408. Target conditions include Deep Vein Thrombosis, Pulmonary Embolism.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00187408 | Approved | Completed |
Competing Products
20 competing products in Deep Vein Thrombosis